Preclinical assessment of galunisertib (LY2157299 monohydrate), a first-in-class transforming growth factor-β receptor type I inhibitor

Jonathan M. Yingling, William T. McMillen, Lei Yan, Huocong Huang, J. Scott Sawyer, Jeremy Graff, David K. Clawson, Karen S. Britt, Bryan D. Anderson, Douglas W. Beight, Durisala Desaiah, Michael M. Lahn, Karim A. Benhadji, Maria J. Lallena, Rikke B. Holmgaard, Xiaohong Xu, Faming Zhang, Jason R. Manro, Philip W. Iversen, Chandrasekar V. Iyer & 3 others Rolf A. Brekken, Michael D. Kalos, Kyla E. Driscoll

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Transforming growth factor-β (TGFβ) is an important driver of tumor growth via intrinsic and extrinsic mechanisms, and is therefore an attractive target for developing cancer therapeutics. Using preclinical models, we characterized the antitumor activity of a small molecule inhibitor of TGFβ receptor I (TGFβRI), galunisertib (LY2157299 monohydrate). Galunisertib demonstrated potent and selective inhibition of TGFβRI with corresponding inhibition of downstream signaling via inhibition of SMAD phosphorylation (pSMAD). Galunisertib also inhibited TGFβ-induced pSMAD in vivo, which enabled a pharmacokinetic/pharmacodynamic profile in Calu6 and EMT6-LM2 tumors. Galunisertib demonstrated anti-tumor activity including inhibition of tumor cell migration and mesenchymal phenotype, reversal of TGFβ-mediated immune-suppression, and tumor growth delay. A concentration-effect relationship was established with a dosing schedule to achieve the optimal level of target modulation. Finally, a rat model demonstrated a correlation between galunisertibdependent inhibition of pSMAD in tumor tissues and in PBMCs, supporting the use of PBMCs for assessing pharmacodynamic effects. Galunisertib has been tested in several clinical studies with evidence of antitumor activity observed in subsets of patients. Here, we demonstrate that galunisertib inhibits a number of TGFβ-dependent functions leading to anti-tumor activity. The enhanced understanding of galunisertib provides rationale for further informed clinical development of TGFβ pathway inhibitors.

Original languageEnglish (US)
Pages (from-to)6659-6677
Number of pages19
JournalOncotarget
Volume9
Issue number6
DOIs
StatePublished - Jan 1 2018

Fingerprint

LY-2157299
Growth Factor Receptors
Transforming Growth Factors
Neoplasms
Cell Migration Inhibition
Growth

Keywords

  • Galunisertib
  • LY2157299
  • SMAD
  • TGFβ receptor I

ASJC Scopus subject areas

  • Oncology

Cite this

Yingling, J. M., McMillen, W. T., Yan, L., Huang, H., Sawyer, J. S., Graff, J., ... Driscoll, K. E. (2018). Preclinical assessment of galunisertib (LY2157299 monohydrate), a first-in-class transforming growth factor-β receptor type I inhibitor. Oncotarget, 9(6), 6659-6677. https://doi.org/10.18632/oncotarget.23795

Preclinical assessment of galunisertib (LY2157299 monohydrate), a first-in-class transforming growth factor-β receptor type I inhibitor. / Yingling, Jonathan M.; McMillen, William T.; Yan, Lei; Huang, Huocong; Sawyer, J. Scott; Graff, Jeremy; Clawson, David K.; Britt, Karen S.; Anderson, Bryan D.; Beight, Douglas W.; Desaiah, Durisala; Lahn, Michael M.; Benhadji, Karim A.; Lallena, Maria J.; Holmgaard, Rikke B.; Xu, Xiaohong; Zhang, Faming; Manro, Jason R.; Iversen, Philip W.; Iyer, Chandrasekar V.; Brekken, Rolf A.; Kalos, Michael D.; Driscoll, Kyla E.

In: Oncotarget, Vol. 9, No. 6, 01.01.2018, p. 6659-6677.

Research output: Contribution to journalArticle

Yingling, JM, McMillen, WT, Yan, L, Huang, H, Sawyer, JS, Graff, J, Clawson, DK, Britt, KS, Anderson, BD, Beight, DW, Desaiah, D, Lahn, MM, Benhadji, KA, Lallena, MJ, Holmgaard, RB, Xu, X, Zhang, F, Manro, JR, Iversen, PW, Iyer, CV, Brekken, RA, Kalos, MD & Driscoll, KE 2018, 'Preclinical assessment of galunisertib (LY2157299 monohydrate), a first-in-class transforming growth factor-β receptor type I inhibitor', Oncotarget, vol. 9, no. 6, pp. 6659-6677. https://doi.org/10.18632/oncotarget.23795
Yingling, Jonathan M. ; McMillen, William T. ; Yan, Lei ; Huang, Huocong ; Sawyer, J. Scott ; Graff, Jeremy ; Clawson, David K. ; Britt, Karen S. ; Anderson, Bryan D. ; Beight, Douglas W. ; Desaiah, Durisala ; Lahn, Michael M. ; Benhadji, Karim A. ; Lallena, Maria J. ; Holmgaard, Rikke B. ; Xu, Xiaohong ; Zhang, Faming ; Manro, Jason R. ; Iversen, Philip W. ; Iyer, Chandrasekar V. ; Brekken, Rolf A. ; Kalos, Michael D. ; Driscoll, Kyla E. / Preclinical assessment of galunisertib (LY2157299 monohydrate), a first-in-class transforming growth factor-β receptor type I inhibitor. In: Oncotarget. 2018 ; Vol. 9, No. 6. pp. 6659-6677.
@article{d397c57831554f318f2d5e0c0ade9663,
title = "Preclinical assessment of galunisertib (LY2157299 monohydrate), a first-in-class transforming growth factor-β receptor type I inhibitor",
abstract = "Transforming growth factor-β (TGFβ) is an important driver of tumor growth via intrinsic and extrinsic mechanisms, and is therefore an attractive target for developing cancer therapeutics. Using preclinical models, we characterized the antitumor activity of a small molecule inhibitor of TGFβ receptor I (TGFβRI), galunisertib (LY2157299 monohydrate). Galunisertib demonstrated potent and selective inhibition of TGFβRI with corresponding inhibition of downstream signaling via inhibition of SMAD phosphorylation (pSMAD). Galunisertib also inhibited TGFβ-induced pSMAD in vivo, which enabled a pharmacokinetic/pharmacodynamic profile in Calu6 and EMT6-LM2 tumors. Galunisertib demonstrated anti-tumor activity including inhibition of tumor cell migration and mesenchymal phenotype, reversal of TGFβ-mediated immune-suppression, and tumor growth delay. A concentration-effect relationship was established with a dosing schedule to achieve the optimal level of target modulation. Finally, a rat model demonstrated a correlation between galunisertibdependent inhibition of pSMAD in tumor tissues and in PBMCs, supporting the use of PBMCs for assessing pharmacodynamic effects. Galunisertib has been tested in several clinical studies with evidence of antitumor activity observed in subsets of patients. Here, we demonstrate that galunisertib inhibits a number of TGFβ-dependent functions leading to anti-tumor activity. The enhanced understanding of galunisertib provides rationale for further informed clinical development of TGFβ pathway inhibitors.",
keywords = "Galunisertib, LY2157299, SMAD, TGFβ receptor I",
author = "Yingling, {Jonathan M.} and McMillen, {William T.} and Lei Yan and Huocong Huang and Sawyer, {J. Scott} and Jeremy Graff and Clawson, {David K.} and Britt, {Karen S.} and Anderson, {Bryan D.} and Beight, {Douglas W.} and Durisala Desaiah and Lahn, {Michael M.} and Benhadji, {Karim A.} and Lallena, {Maria J.} and Holmgaard, {Rikke B.} and Xiaohong Xu and Faming Zhang and Manro, {Jason R.} and Iversen, {Philip W.} and Iyer, {Chandrasekar V.} and Brekken, {Rolf A.} and Kalos, {Michael D.} and Driscoll, {Kyla E.}",
year = "2018",
month = "1",
day = "1",
doi = "10.18632/oncotarget.23795",
language = "English (US)",
volume = "9",
pages = "6659--6677",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "6",

}

TY - JOUR

T1 - Preclinical assessment of galunisertib (LY2157299 monohydrate), a first-in-class transforming growth factor-β receptor type I inhibitor

AU - Yingling, Jonathan M.

AU - McMillen, William T.

AU - Yan, Lei

AU - Huang, Huocong

AU - Sawyer, J. Scott

AU - Graff, Jeremy

AU - Clawson, David K.

AU - Britt, Karen S.

AU - Anderson, Bryan D.

AU - Beight, Douglas W.

AU - Desaiah, Durisala

AU - Lahn, Michael M.

AU - Benhadji, Karim A.

AU - Lallena, Maria J.

AU - Holmgaard, Rikke B.

AU - Xu, Xiaohong

AU - Zhang, Faming

AU - Manro, Jason R.

AU - Iversen, Philip W.

AU - Iyer, Chandrasekar V.

AU - Brekken, Rolf A.

AU - Kalos, Michael D.

AU - Driscoll, Kyla E.

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Transforming growth factor-β (TGFβ) is an important driver of tumor growth via intrinsic and extrinsic mechanisms, and is therefore an attractive target for developing cancer therapeutics. Using preclinical models, we characterized the antitumor activity of a small molecule inhibitor of TGFβ receptor I (TGFβRI), galunisertib (LY2157299 monohydrate). Galunisertib demonstrated potent and selective inhibition of TGFβRI with corresponding inhibition of downstream signaling via inhibition of SMAD phosphorylation (pSMAD). Galunisertib also inhibited TGFβ-induced pSMAD in vivo, which enabled a pharmacokinetic/pharmacodynamic profile in Calu6 and EMT6-LM2 tumors. Galunisertib demonstrated anti-tumor activity including inhibition of tumor cell migration and mesenchymal phenotype, reversal of TGFβ-mediated immune-suppression, and tumor growth delay. A concentration-effect relationship was established with a dosing schedule to achieve the optimal level of target modulation. Finally, a rat model demonstrated a correlation between galunisertibdependent inhibition of pSMAD in tumor tissues and in PBMCs, supporting the use of PBMCs for assessing pharmacodynamic effects. Galunisertib has been tested in several clinical studies with evidence of antitumor activity observed in subsets of patients. Here, we demonstrate that galunisertib inhibits a number of TGFβ-dependent functions leading to anti-tumor activity. The enhanced understanding of galunisertib provides rationale for further informed clinical development of TGFβ pathway inhibitors.

AB - Transforming growth factor-β (TGFβ) is an important driver of tumor growth via intrinsic and extrinsic mechanisms, and is therefore an attractive target for developing cancer therapeutics. Using preclinical models, we characterized the antitumor activity of a small molecule inhibitor of TGFβ receptor I (TGFβRI), galunisertib (LY2157299 monohydrate). Galunisertib demonstrated potent and selective inhibition of TGFβRI with corresponding inhibition of downstream signaling via inhibition of SMAD phosphorylation (pSMAD). Galunisertib also inhibited TGFβ-induced pSMAD in vivo, which enabled a pharmacokinetic/pharmacodynamic profile in Calu6 and EMT6-LM2 tumors. Galunisertib demonstrated anti-tumor activity including inhibition of tumor cell migration and mesenchymal phenotype, reversal of TGFβ-mediated immune-suppression, and tumor growth delay. A concentration-effect relationship was established with a dosing schedule to achieve the optimal level of target modulation. Finally, a rat model demonstrated a correlation between galunisertibdependent inhibition of pSMAD in tumor tissues and in PBMCs, supporting the use of PBMCs for assessing pharmacodynamic effects. Galunisertib has been tested in several clinical studies with evidence of antitumor activity observed in subsets of patients. Here, we demonstrate that galunisertib inhibits a number of TGFβ-dependent functions leading to anti-tumor activity. The enhanced understanding of galunisertib provides rationale for further informed clinical development of TGFβ pathway inhibitors.

KW - Galunisertib

KW - LY2157299

KW - SMAD

KW - TGFβ receptor I

UR - http://www.scopus.com/inward/record.url?scp=85040944996&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85040944996&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.23795

DO - 10.18632/oncotarget.23795

M3 - Article

VL - 9

SP - 6659

EP - 6677

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 6

ER -